Merck foresees healthy growth ahead in Indonesia

31 March 2016

Publicly listed Merck, founded in 1970 as the Indonesian unit of German life science group Merck KGaA (MRK: DE), expects double-digit growth in total sales in 2016 following a similar growth in its healthcare business last year.

The biopharma business, for example, rose by 14.5% in 2015, above the industry average of 8% to 9%. On the other hand, the consumer health business soared by 16%, according to the Jakarta Post.

The Indonesia unit will also strengthen its current strategy of maintaining partnerships with both private and government organizations such as the Health Ministry and the Jakarta Administration, through which Merck will expand public awareness about health issues, encourage public acceptance and broaden market access for Merck's pharmaceutical products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK